Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency
Open Access
- 8 August 2011
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1), 133-143
- https://doi.org/10.1111/j.1463-1326.2011.01455.x
Abstract
In health, the pancreatic islet cells work as a network with highly co‐ordinated signals over time to balance glycaemia within a narrow range. In type 1 diabetes (T1DM), with autoimmune destruction of the β‐cells, lack of insulin is considered the primary abnormality and is the primary therapy target. However, replacing insulin alone does not achieve adequate glucose control and recent studies have focused on controlling the endogenous glucagon release as well. In T1DM, glucagon secretion is disordered but not absolutely deficient; it may be excessive postprandially yet it is characteristically insufficient and delayed in response to hypoglycaemia. We review our system‐level analysis of the pancreatic endocrine network mechanisms of glucagon counterregulation (GCR) and their dysregulation in T1DM and focus on possible use of α‐cell inhibitors (ACIs) to manipulate the glucagon axis to repair the defective GCR. Our results indicate that the GCR abnormalities are of ‘network origin’. The lack of β‐cell signalling is the primary deficiency that contributes to two separate network abnormalities: (i) absence of a β‐cell switch‐off trigger and (ii) increased intraislet basal glucagon. A strategy to repair these abnormalities with ACI is proposed, which could achieve better control of glycaemia with reduced hypoglycaemia risk.Keywords
This publication has 76 references indexed in Scilit:
- Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in MiceDiabetes, 2011
- Paracrinology of islets and the paracrinopathy of diabetesProceedings of the National Academy of Sciences of the United States of America, 2010
- A Bihormonal Closed-Loop Artificial Pancreas for Type 1 DiabetesScience Translational Medicine, 2010
- Leptin therapy in insulin-deficient type I diabetesProceedings of the National Academy of Sciences of the United States of America, 2010
- Chapter 21 Pancreatic Network Control of Glucagon Secretion and CounterregulationMethods in Enzymology, 2009
- AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: Description and validation using synthetic dataAnalytical Biochemistry, 2008
- Amplification of pulsatile glucagon counterregulation by switch-off of α-cell-suppressing signals in streptozotocin-treated ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusionDiabetologia, 1979